Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How I treat refractory CLL.

Emili Montserrat1, Carol Moreno, Jordi Esteve

  • 1Institute of Hematology and Oncology, Department of Hematology, Hospital Clínic, Villarroel, 170, 08036 Barcelona, Spain. emontse@clinic.ub.es

Blood
|October 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy.

Open forum infectious diseases·2026
Same author

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

HemaSphere·2026
Same author

Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.

British journal of haematology·2026
Same author

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.

Frontiers in immunology·2026
Same author

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain.

Journal for immunotherapy of cancer·2026
Same author

Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology·2026
Same journal

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same journal

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same journal

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
See all related articles

Chronic lymphocytic leukemia (CLL) therapy has advanced with new agents and monoclonal antibodies. Allogeneic stem cell transplantation offers a cure, especially for refractory CLL, with reduced-intensity options improving safety.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Chronic lymphocytic leukemia (CLL) treatment has evolved from ineffective alkylators to purine analogs and monoclonal antibodies.
  • Refractory CLL presents significant therapeutic challenges, necessitating careful patient and disease evaluation.
  • Distinguishing refractory from relapsing disease is crucial for appropriate treatment selection.

Purpose of the Study:

  • To review current therapeutic strategies for chronic lymphocytic leukemia (CLL).
  • To discuss the role and limitations of allogeneic stem cell transplantation in CLL management.
  • To highlight challenges and future directions in treating refractory CLL.

Main Methods:

  • Review of current literature on CLL therapies.

Related Experiment Videos

  • Analysis of treatment outcomes for refractory and relapsing CLL.
  • Evaluation of allogeneic stem cell transplantation, including nonmyeloablative approaches.

    • Main Results:

    • Novel agents and monoclonal antibodies have improved CLL treatment efficacy.
    • Allogeneic stem cell transplantation is the only curative option for CLL, including refractory cases.
    • Nonmyeloablative regimens may reduce transplant-related mortality, expanding transplant eligibility.

    Conclusions:

    • Treatment for CLL has significantly improved, but refractory disease remains challenging.
    • Allogeneic stem cell transplantation, particularly with reduced-intensity conditioning, offers curative potential.
    • Further research is needed to overcome therapy resistance and identify patients benefiting from early, intensive treatments.